Skip to main content
Clinical Trials/NCT02369133
NCT02369133
Completed
Phase 4

Preemptive Analgesia With Intravenous Paracetamol for Post-cesarean Section Pain Control : A Randomized Controlled Trial

Baskent University0 sites60 target enrollmentNovember 2013

Overview

Phase
Phase 4
Intervention
paracetamol
Conditions
Cesarean Section; Dehiscence
Sponsor
Baskent University
Enrollment
60
Primary Endpoint
Postoperative pain scores measured by visual analog scale (VAS)
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The investigators designed a prospective randomized study to investigate the efficacy of intravenous (IV) preemptive paracetamol on postoperative pain scores, patient satisfaction, total morfin consumption and the incidence of morfin-related side effects in patients undergoing cesarean section.

Registry
clinicaltrials.gov
Start Date
November 2013
End Date
November 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ozlem Ozmete

Medical Doctor

Baskent University

Eligibility Criteria

Inclusion Criteria

  • Patients between the ages of 20-40 years,
  • ASA physical status 1-2 who underwent elective cesarean surgery during general anesthesia were included in the study

Exclusion Criteria

  • A history of allergy to any of the study medications (opiod, general anesthetic agents or paracetamol),
  • history of opioid or paracetamol use,
  • hepatic or renal failure,
  • any psychological disorders,
  • complications during cesarean section and unable to use PCIA device were excluded from the study.

Arms & Interventions

Group Paracetamol (Group P),

Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol

Intervention: paracetamol

Group Saline (Group S)

Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group S (n = 30) received 100 ml iv %0,9 saline

Intervention: Placebo

Outcomes

Primary Outcomes

Postoperative pain scores measured by visual analog scale (VAS)

Time Frame: Postoperative 24 hours

Similar Trials